Mark L. Levitt
Impact in
- Oncology top 2%
- Cancer-related Molecular Pathways
- Lung Cancer Research Studies
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 19
- Lung Cancer Research Studies 5
- Peptidase Inhibition and Analysis 4
- Colorectal Cancer Treatments and Studies 3
-
- Cell death mechanisms and regulation 4
- PI3K/AKT/mTOR signaling in cancer 3
- Co-authors
- John D. Minna (2 shared papers)Richard K. Rosenberg (1 shared paper)Adi F. Gazdar (1 shared paper)Itsuo Chiba (1 shared paper)Michelle Vinocour (1 shared paper)Marion M. Nau (1 shared paper)Michael J. Birrer (1 shared paper)Harvey I. Pass (1 shared paper)
- Journals
- Lung Cancer (8 papers)Journal of Clinical Oncology (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Cancer Research (2 papers)Journal of Leukocyte Biology (2 papers)
- Partner nations
- United StatesIsraelChina
In The Last Decade
Mark L. Levitt
40 papers receiving 1.8k citations
Mark L. Levitt's Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 1000
- Cancer Research 325
- Biotechnology 193
- Pulmonary and Respiratory Medicine 414
- Molecular Biology 744
Countries citing papers authored by Mark L. Levitt
This map shows the geographic impact of Mark L. Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Levitt more than expected).
Fields of papers citing papers by Mark L. Levitt
This network shows the impact of papers produced by Mark L. Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Levitt. The network helps show where Mark L. Levitt may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark L. Levitt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | p53: A Frequent Target for Genetic Abnormalities in Lung Cancer Hit paper breakdown → | 1989 | 1054 |
| 2 | 2006 | 134 | |
| 3 | 1989 | 116 | |
| 4 | 1999 | 70 | |
| 5 | Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. | 1976 | 57 |
| 6 | 1999 | 43 | |
| 7 | 1995 | 41 | |
| 8 | 2007 | 27 | |
| 9 | 1995 | 25 | |
| 10 | 2003 | 23 | |
| 11 | 1999 | 23 | |
| 12 | 1998 | 22 | |
| 13 | 1999 | 20 | |
| 14 | Sequential methotrexate and 5-FU in the treatment of colorectal cancer. | 1982 | 20 |
| 15 | 2022 | 17 | |
| 16 | Oat cell carcinoma of the lung: CNS metastases in spite of prophylactic brain irradiation. | 1978 | 17 |
| 17 | 1997 | 17 | |
| 18 | 1998 | 15 | |
| 19 | 1998 | 14 | |
| 20 | 2009 | 13 |
About Mark L. Levitt
Mark L. Levitt is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 43 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (5 papers), Peptidase Inhibition and Analysis (4 papers), Cell death mechanisms and regulation (4 papers), Blood properties and coagulation (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Immunotherapy and Immune Responses (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Oncology (1000 citations), Cancer Research (325 citations), Biotechnology (193 citations), Pulmonary and Respiratory Medicine (414 citations) and Molecular Biology (744 citations). Mark L. Levitt has collaborated with scholars based in United States, Israel and China. Frequent co-authors include John D. Minna, Richard K. Rosenberg, Adi F. Gazdar, Itsuo Chiba, Michelle Vinocour, Marion M. Nau, Michael J. Birrer, Harvey I. Pass, Takashi Takahashi and Patrick P. Koty. Their work appears in journals such as Lung Cancer, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research and Journal of Leukocyte Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.